用[18F]胆碱PET显像检测三阴性乳腺癌动物模型中的代谢适应作为耐药性的替代标志
研究在三阴性乳腺癌(TNBC)小鼠移植瘤模型中测试基于影像的方法识别紫杉烷耐药的可行性。将紫杉醇敏感和耐药TNBC细胞(MDA-MD-346)原位注射至雌性NOD-SCID小鼠,肿瘤达100-150 mm3时行[18F]胆碱PET/CT,取瘤行放射自显影和免疫荧光分析。共扫描15只小鼠,结果显示经治疗和未治疗的紫杉醇敏感与耐药细胞系具有不同的代谢特性,可在化疗开始前加以利用。
要点
- 在TNBC小鼠移植瘤模型中,[18F]胆碱PET/CT可用于检测肿瘤代谢摄取差异。
- 紫杉醇敏感与耐药细胞系在治疗前后经血池归一化后均显示代谢摄取差异。
- 经治疗与未治疗的敏感和耐药细胞系具有不同代谢特性,或可在化疗前利用。
核心结论
- 经治疗和未治疗的紫杉醇敏感与耐药细胞系具有不同的代谢特性,可在化疗开始前加以利用。
研究设计与样本
- 研究为动物实验,将紫杉醇敏感和紫杉醇耐药TNBC细胞(MDA-MD-346)原位注射至雌性NOD-SCID小鼠生成移植瘤模型。
- 肿瘤达100-150 mm3时行[18F]胆碱PET/CT扫描,取瘤切片行放射自显影和免疫荧光分析并定量分析。
主要发现
- 共扫描15只小鼠,其中5只携带紫杉醇敏感细胞系肿瘤,这5只中2只接受紫杉醇类治疗。
- 其余10只携带紫杉醇耐药细胞系肿瘤,其中4只接受紫杉醇类治疗。
- 仅13只小鼠有肿瘤样本进行组织学分析。
- 经血池归一化后,两种细胞系在治疗前后均显示代谢摄取差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Test the feasibility of an image-based method to identify taxane resistance in mouse bearing triple-negative breast cancer (TNBC) tumor xenografts. METHODS: Xenograft tumor-bearing mice from paclitaxel-sensitive and paclitaxel-resistant TNBC cells (MDA-MD-346) were generated by orthotopic injection into female NOD-SCID mice. When tumors reached 100-150 mm3, mice were scanned using [18F]choline PET/CT. Tumors were collected and sliced for autoradiography and immunofluorescence analysis. Quantitative data was analyzed accordingly. RESULTS: From fifteen mice scanned, five had taxane-sensitive cell line tumors of which two underwent taxol-based treatment. From the remaining 10 mice with taxane-resistant cell line tumors, four underwent taxol-based treatment. Only 13 mice had the tumor sample analyzed histologically. When normalized to the blood pool, both cell lines showed differences in metabolic uptake before and after treatment. CONCLUSIONS: Treated and untreated taxane-sensitive and taxane-resistant cell lines have different metabolic properties that could be leveraged before the start of chemotherapy.
引用
- Kohan AA, Lupien M, Cescon D, et al. Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance. Eur J Nucl Med Mol Imaging. 2023. PMID: 38095672. doi:10.1007/s00259-023-06546-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。